SCHEMBL6532251

SCHEMBL6532251

OC(c1ccccc1)c1cn[nH]c1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.50
AKT2 P31751 2/20 0.45
AKT1 P31749 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.39
ALDH1A1 P00352 1/20 0.38
ROCK1 Q13464 5/20 0.37
MYLK4 Q86YV6 4/20 0.37
ROCK2 O75116 3/20 0.36
LMNA P02545 1/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
CA14 Q9ULX7 1/20 0.36
HPGD P15428 1/20 0.36
SRD5A2 P31213 1/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14033465 0.81 AKT2 (0.46) AKT2AKT1ROCK1ROCK2
SCHEMBL2375241 0.79 AKT2 (0.48) AKT2AKT1ROCK1MYLK4ROCK2
SCHEMBL16156937 0.76 AKT2 (0.45) AKT2AKT1ROCK1ROCK2LMNA
SCHEMBL17875272 0.76 AKT2 (0.47) AKT2AKT1ROCK1MYLK4ROCK2
SCHEMBL7999525 0.76 AKT2 (0.50) AKT2AKT1ALDH1A1ROCK1MYLK4
SCHEMBL1560439 0.76 AKT2 (0.41) AKT2AKT1L3MBTL1ROCK1MYLK4
SCHEMBL30290968 0.76 IDO1 (0.45) AKT2AKT1ROCK2
Diphenylmethanol SCHEMBL10868602 0.75 SMN1; SMN2 (0.61) SMN1; SMN2L3MBTL1LMNACA12CA1
Diphenylmethanol SCHEMBL11564700 0.75 SMN1; SMN2 (0.61) SMN1; SMN2L3MBTL1LMNACA12CA1
Diphenylmethanol SCHEMBL41571 0.75 SMN1; SMN2 (0.61) SMN1; SMN2L3MBTL1LMNACA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260116881-A1 KIF MODULATOR COMPOUNDS AND METHODS OF USE IAMBIC THERAPEUTICS INC (US) 2026-04-30 US disclosed
EP-1572200-A1 AMINOINDAZOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS Aventis Pharma S.A. (FR) 2005-09-14 EP disclosed
WO-2005040127-A1 NOVEL COMPOUNDS AS AGONIST FOR PPAR GAMMA AND PPAR ALPHA, METHOD FOR PREPARATION OF THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME LG LIFE SCIENCES LTD. (KR) 2005-05-06 WO disclosed
WO-2004062662-A1 AMINOINDAZOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2004-07-29 WO disclosed
EP-0424021-B1 Antimuscarinic bronchodilators PFIZER LTD (GB) 1994-03-02 EP disclosed
CN-1022488-C Antimuscainic bronchodilators PFIZER (US) 1993-10-20 CN disclosed
US-5171744-A Antimuscarinic bronchodilators PFIZER INC. (US) 1992-12-15 US disclosed
CN-1051041-A Antimuscainic bronchodilators PFIZER (US) 1991-05-01 CN disclosed
EP-0424021-A1 Antimuscarinic bronchodilators Pfizer Limited (GB) 1991-04-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260116881-A1 KIF MODULATOR COMPOUNDS AND METHODS OF USE KIF2C, KIF5B, KIF5C SMN1; SMN2 218/4885AKT2 1848/4885AKT1 2871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.